Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.
复制标题
靶向 O-乙酰基-GD2 神经节苷脂用于癌症免疫治疗。
DOI：
10.1155/2017/5604891
复制
发表时间：
2017
影响因子：
4.1
通讯作者：
Birklé S
中科院分区：
文献类型：
--
作者：
Fleurence J;Fougeray S;Bahri M;Cochonneau D;Clémenceau B;Paris F;Heczey A;Birklé S
肿瘤免疫治疗是肿瘤研究的一个重要领域，靶点选择是肿瘤免疫治疗的一个重要特征。在这方面，神经节苷脂是一个广泛的结构相关的糖脂家族，由于其在肿瘤中的丰度高于匹配的正常组织，因此被认为是癌症免疫治疗的潜在靶点。GD2是第一个被证明是癌症免疫治疗有效靶抗原的神经节苷脂，并获得了抗GD2嵌合治疗性抗体迪努昔单抗的监管批准。尽管抗GD2单抗的治疗效果已有文献记载，但神经病理性疼痛可能会限制其应用。O-乙酰-GD2是GD2的O-乙酰化衍生物，最近作为靶向GD2阳性肿瘤的新抗原而受到关注。本论文研究了O-乙酰-GD2在肿瘤生物学中的作用以及现有的抗O-乙酰-GD2单抗的临床前数据。还讨论了O-乙酰-GD2在嵌合抗原受体T细胞治疗发展中的相关性。
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.